Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report

This case report describes a 28-year-old female with systemic lupus erythematosus (SLE) and post-surgical papillary thyroid carcinoma (PTC) who was treated with telitacicept. Initially, her SLE was managed with glucocorticoids, mycophenolate mofetil, and cyclosporine, which improved most symptoms but not complement levels C3 and C4. After thyroid carcinoma surgery, telitacicept was administered, resulting in the normalization and stabilization of complement levels. This is the first documented case of telitacicept being used in such a context, indicating its potential as a therapeutic option for similar cases. However, further research and randomized controlled trials are necessary to validate these findings and ensure safety.